
ESSA Pharma Inc
NASDAQ:EPIX

Fundamental Analysis


Revenue & Expenses Breakdown
ESSA Pharma Inc
Balance Sheet Decomposition
ESSA Pharma Inc
Current Assets | 115.2m |
Cash & Short-Term Investments | 113.9m |
Receivables | 415.5k |
Other Current Assets | 879.4k |
Non-Current Assets | 248k |
PP&E | 248k |
Free Cash Flow Analysis
ESSA Pharma Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
ESSA Pharma Inc
Revenue
|
0
USD
|
Cost of Revenue
|
-125.5k
USD
|
Gross Profit
|
-125.5k
USD
|
Operating Expenses
|
-33.3m
USD
|
Operating Income
|
-33.4m
USD
|
Other Expenses
|
4.9m
USD
|
Net Income
|
-28.5m
USD
|
EPIX Profitability Score
Profitability Due Diligence
ESSA Pharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Score
ESSA Pharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
EPIX Solvency Score
Solvency Due Diligence
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPIX Price Targets Summary
ESSA Pharma Inc
According to Wall Street analysts, the average 1-year price target for
EPIX
is 1.73 USD
with a low forecast of 1.72 USD and a high forecast of 1.79 USD.
Dividends
Current shareholder yield for EPIX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?